For twenty years Judges Scientific built its strategy around one repeatable thing: buy small, world-leading scientific-instrument businesses at low multiples, leave them alone, and let cash compound. The record — ~25% a year — is the kind serial-acquirer investors dream about. Then the engine spluttered: organic orders softened, a lumpy Geotek expedition flattered the numbers, US research funding froze, and the shares fell roughly two-thirds. The question is no longer whether the model worked — it plainly did — but whether the law of large numbers, thin deal supply and cyclical demand now cap it.

In FY2025 Judges reported revenue of £145.8m (+9.1%), but adjusted operating profit was broadly flat at £28.0m and pretax profit fell 32% to £8.9m after a £9.7m amortisation charge, a £4.2m impairment and a £1.4m swap write-down; attributable profit dropped to £5.5m from £10.4m[1][26]. Strip out a one-off Geotek coring expedition and adjusted operating profit fell about a third[19]. The company began 2026 "with a lower-than-desired order book" and 2026 order intake down ~17%[2]. The shares, which peaked at £122.50 in May 2024, traded near £42 by mid-2026 — down roughly two-thirds[4]. This site lays out the bull and bear case on each and leaves the judgment to you.

Revenue kept rising — but the profit engine stalled

Judges' top line has compounded steadily through acquisitions and organic growth, crossing £100m after the 2022 Geotek deal and reaching £145.8m in 2025[1]. But revenue is the flattering line. Adjusted operating profit was flat in 2025, and once the cyclical Geotek coring expedition is removed, underlying profit fell about a third — a reminder that this is a portfolio of small, individually volatile businesses, not a smooth compounder[19].

Revenue from results coverage; 2021–2023 figures are indicative of the trajectory around the Geotek acquisition, with FY2024 and FY2025 disclosed[1]. Geotek (2022) lifted scale but added lumpy coring-expedition revenue; see Segments & Geotek.

The four questions this case study turns on

The balance of evidence, at a glance

Judges Scientific is a portfolio of roughly 20 niche scientific-instrument businesses assembled through about 25 acquisitions since 2005[8]. Founder David Cicurel built it from a £2002 shell into a compounder that returned ~25% a year — and in February 2026 handed the CEO role to Dr Tim Prestidge while staying on as chair and chief dealmaker[6].

From shell company to scientific-instrument roll-up

Judges was incorporated in November 2002 (Companies House number 04597315) as a vehicle to acquire and resell small public companies[5]. The decisive turn came in May 2005, when Cicurel bought Fire Testing Technology and recognised a pattern: Britain is full of small, often founder-owned firms that quietly dominate a global niche in scientific measurement — fire testing, fibre-optic test gear, vacuum components, materials testing — with strong pricing power and modest valuations[5][8]. Buying these one at a time, cheaply, and leaving them to run became the entire strategy.

Over the next two decades Judges added a business roughly once or twice a year: Scientifica, Armfield, GDS Instruments, Quorum Technologies, Deben, Oxford Cryosystems, Dia-Stron, Teer Coatings and more, organised into two segments — Materials Sciences and Vacuum[8][16]. The 2022 Geotek deal was a step-change in size and changed the profit profile (see Segments & Geotek).

A two-decade timeline

The founder, and the handover

David Cicurel ran Judges as CEO for two decades and remains its largest individual shareholder, with about 9.2% of the company (down from ~11% in 2022), alongside a largely institutional register[22]. His departure from day-to-day leadership had long been the headline governance risk. In the event the transition was orderly and pre-planned: effective 9 February 2026, Cicurel became Non-Executive Chair and Dr Tim Prestidge — who joined Judges in February 2023 after divisional-CEO roles at Halma and Renishaw — was promoted to CEO[6]. Critically, Cicurel did not leave the part of the job that matters most for this model: he stays "actively engaged" in the acquisition process[6][7].

Judges' end market is global laboratory and industrial-research instrumentation: thousands of small, defensible niches with pricing power but demand tied to academic and government research budgets. In 2025 that cyclicality bit — the USA, its largest market, cut orders sharply as federal research funding (NIH/NSF) was frozen and slashed[2][10].

A market made of niches

There is no single "scientific instruments" market so much as thousands of micro-markets — fire-resistance testers, fibre-optic measurement rigs, electron-microscope sample stages, cryostats, geotechnical core scanners — each small enough that one firm can dominate it globally and large enough to be a real business. That fragmentation is the structural foundation of Judges' model: management points to "well over 1,000" companies with £1–50m of revenue in its target sectors[9]. Customers are universities, government labs, semiconductor and materials companies, and energy/telecoms researchers — buyers who value precision and reliability over price, which underpins the sector's high margins[21].

The cyclicality the model can't fully escape

The flip side of selling to research labs is that demand follows research budgets — and those are policy-driven and lumpy. Two episodes frame the risk. In China, order intake fell roughly two-thirds in H1 2023 as policy shifted toward consumer stimulus and "Buy Chinese" procurement[30]. In the United States, the 2025 disruption to federal science funding hit demand directly: even though total NIH/NSF dollars stayed roughly flat, agencies sharply cut the number of grants — NSF new research grants fell from ~11,000 to ~8,800 — to limit future commitments against threatened deep cuts, chilling lab capital spending[10].

Bars show the absolute size of the H1-2025 regional swing; the USA (Judges' largest market, highlighted) drove the −10% group organic order intake, partly offset by a China recovery[27]. Source: H1 2025 interim results.

The model is almost mechanical: pay ~5–6x EBIT for niche global leaders, fund ~half with debt, run them hands-off, and earn 50%+ on tangible capital plus low-single-digit organic growth[12][14]. Cicurel calls return on adjusted total invested capital "the key to all our thinking." The risk is not the formula — it's whether there are still enough cheap deals to feed it at a £280m company[15].

The five-step machine

The decisive variable is price. Founders sell to Judges at an average of roughly 4.8x EBIT — far below the 12–14x that trade buyers or private equity pay — because Judges offers integrity, speed, certainty and a promise not to gut the business[12][25]. That discount is the source of the excess return: the same earnings stream simply costs Judges less.

Capital allocation: ROTIC over everything

Management frames the "growth algorithm" as roughly a 13% post-tax return on the initial acquisition price plus 7–9% organic growth, compounding to about 20% a year[13]. Buybacks are rejected unless they are demonstrably the best use of capital, because "acquisitions offer better returns"; the dividend rises steadily but acquisitions get first claim on cash[13]. The lodestar metric is ROTIC — return on adjusted total invested capital — which a typical ~5x-EBIT deal pushes above 50% on tangible capital[14].

Where the model is being tested

The strain shows up in deployment. In 2025, Judges deployed only £1.9m of acquisition capital — a minority stake in Geotek do Brasil — far short of what compounding at scale requires[15]. Management has responded by hiring a dedicated Group Acquisitions Executive and pushing to widen the funnel internationally, while conceding the company is "less well-known outside the UK"[15]. The bull reads thin deployment as discipline (no cheap deals, so no deals); the bear reads it as the early signature of a deal-supply ceiling.

The two segments — Materials Sciences (~53%) and Vacuum (~47%) — are a sensible way to group ~20 micro-businesses[16]. But the swing factor is Geotek: its ~£11m coring expedition in 2025 flattered the result, and stripping it out, FY2025 underlying operating profit fell about a third[18][19].

Two segments, twenty businesses

Judges organises its portfolio into Materials Sciences (microscopy sample preparation, surface coatings, materials and geotechnical testing) and Vacuum (vacuum components and systems for semiconductors and research)[16]. The two are roughly balanced, which gives the group some diversification — but each segment is itself a collection of small, individually volatile niche leaders, so smooth segment totals can mask sharp swings underneath.

Approximate split from independent analysis of Judges' segment reporting[16]; segment composition shifts year to year with acquisitions and the Geotek coring cycle.

The Geotek question

Geotek, bought in May 2022 for up to £80m (£45m upfront plus up to £35m contingent) at about 7x EBIT, was Judges' largest acquisition and a deliberate step up in deal size[17]. It makes instruments that measure and log geological cores (MSCL) and — unusually for Judges — sells coring services, including marine coring expeditions for scientific drilling programmes[17][18]. Those expeditions are large, profitable and lumpy: a single 2025 expedition restored Geotek to roughly £11m EBIT and was the main prop under FY2025 profit[18].

Each Judges business is a near-monopoly in a tiny niche, so product rivalry is low. The pressure point is the market for deals: rivals pay 12–14x EBIT versus Judges' ~5–6x, and larger acquirers plus 2025's surge of private-equity interest in instrument assets make cheap micro-deals scarcer[25][35].

Five forces — read through the acquirer's lens

A conventional Five Forces analysis of Judges' products looks benign: defensible niches, weak substitutes, sticky customers. The honest version recognises that Judges is as much a capital allocator as an instrument maker, so the binding force is rivalry for acquisitions. Click each force for the evidence.

Positioning: small, disciplined, specialised

Among serial acquirers, Judges sits at the smallest, most disciplined, most specialised corner: ~20 operating companies bought at ~6x EBIT, against Halma's ~50 at ~7.5x and the larger, pricier deal styles of Diploma and Danaher[20][24]. That positioning is the source of both its superior margins and its scale ceiling.

Qualitative placement from cited serial-acquirer analysis; axes are relative, not to scale[20][24][35].

The moat is two-layered: a portfolio of niche near-monopolies with pricing power, sitting under a reputational acquisition advantage that lets Judges buy cheaply[12][21]. Both layers are people-dependent — which is why the February-2026 CEO handover to Tim Prestidge matters so much[6].

Stated strategy vs. revealed strategy

What Judges says and what it does closely track each other: acquire global niche leaders, run them hands-off, prioritise ROTIC, and let cash compound into the next deal[13][14]. The revealed strategy adds two nuances the official line understates: a willingness to scale up deal size (Geotek at 7x) when the right asset appears, and a growing need to hunt for deals internationally as the UK funnel matures[15][17].

Sources of durable advantage

• Reputation / trust. Aging founders sell cheaply (~4.8x EBIT) because Judges is known not to gut businesses, decide fast and honour deals — an advantage rivals paying 12–14x cannot replicate by price alone[12][25].
• Niche pricing power. Each opco leads a small global market with few substitutes, supporting ~20% adjusted EBIT margins, ~400bps above larger peers[21].
• Capital-allocation skill. A 20-year ROTIC-led record of buying well and avoiding over-payment[3][14].

SWOT — held to an even hand

Key-person risk: reduced, not removed

For years the single biggest governance question was "what happens when Cicurel goes?" The February-2026 handover answers part of it: an orderly move to Non-Executive Chair, with Tim Prestidge — an ex-Halma and ex-Renishaw divisional CEO who joined in 2023 — taking over operations[6]. But the part of the job that drives returns — judging which businesses to buy and at what price — still rests heavily on Cicurel, who remains "actively engaged" in acquisitions[6][7]. The succession is well-managed; whether Cicurel's deal-making judgement is transferable is unproven.

Judges buys at the lowest multiples (~6x EBIT) and runs the highest margins (~20%) of the UK serial acquirers, with strong organic growth (~7% over FY08–24)[20][21]. The trade-off: it is also the smallest, with ~20 opcos vs Halma's ~50 — so its compounding is most threatened by deal supply[20][24].

The serial-acquirer benchmark

The natural comparison set is the UK "buy-and-build" cohort — Halma, Diploma and the smaller SDI Group — plus the global template, Danaher, and instrument peers like Renishaw and Spectris. Judges is the niche specialist: it pays less, earns more per pound of revenue, but operates at a fraction of the scale.

Figures are approximate and drawn from cited serial-acquirer analysis; multiples and opco counts vary by source and over time[20][24][35].

Where Judges leads — and where it doesn't

Judges and SDI buy cheapest; the gap to trade/PE buyers (12–14x) is the source of excess returns[25][20].

On margins Judges leads the cohort (~20% adjusted EBIT, ~400bps above Halma/Spirax), and on organic growth it has historically out-grown UK instrument peers (~7% vs ~2–4%)[21][20]. The one metric where it is clearly behind is scale and deal capacity: Halma can absorb 15–20 acquisitions a year; Judges needs only a handful, but those are getting harder to find at the right price[24][15].

FY2025 revenue rose 9.1% to £145.8m, but pretax profit fell 32% to £8.9m after amortisation, a £4.2m impairment and a swap write-down, and attributable profit dropped to £5.5m[1][26]. The shares fell from £122.50 (May 2024) to about £42, cutting the forward P/E from ~40x to ~21x[4][28].

The profit bridge: why a record top line met a falling bottom line

The gap between revenue and profit is the story of 2025. Above the line, a Geotek coring expedition and acquired revenue lifted the top line. Below it, FY2025 carried £9.7m of amortisation, a £4.2m impairment (Armfield goodwill, Scientifica, a Rockwash earn-out) and a £1.4m swap fair-value reduction; operating costs rose to £131.9m and interest to £5.6m as debt-funded deals and rates bit[1][26][23]. Adjusted operating profit was flat at £28.0m — but ex-Geotek, underlying profit fell about a third[19].

A two-thirds fall from the peak

Judges traded, for years, at a premium multiple. The de-rating since May 2024 has been severe.

Peak (£122.50, 15 May 2024) and current (~£42, June 2026) levels are disclosed; intermediate points are indicative of the decline path[4]. 52-week range ~£34.80–£91.20[4].

The de-rating has split the analyst community. In January 2026 Jefferies double-downgraded the stock to "Underperform" from "Buy," while Berenberg cut its price target repeatedly (to 5,600p) yet kept a Buy[28][29]. Some valuation models flag the stock as still overvalued versus price; consensus targets imply meaningful upside (~6,450p)[4]. In other words, even professionals disagree on whether ~21x forward is cheap or fair for a low-single-digit organic grower.

Judges' risks rhyme: a scale ceiling, finite deal supply, organic softness, and research-funding cyclicality all point at the same worry — that the model that compounded at ~25% for two decades is hardest to sustain precisely because it worked[34][15].

The risk register

The forward question is whether 2025 was a trough or a new baseline. Watch three signals: US order intake (a funding-recovery proxy), acquisition deployment (is the funnel re-opening?), and organic growth ex-Geotek[2][15][19]. We lay out three scenarios and leave the weighting to you.

Three scenarios to weigh

What would change the picture

• US order recovery. A rebound in US intake would confirm the cyclical reading; continued weakness would support the structural one[2][10].
• A return to meaningful M&A. A year of normal deployment (well above 2025's £1.9m), especially internationally, would ease the deal-supply fear[15].
• Organic growth ex-Geotek. Re-acceleration above low-single-digits would show the portfolio, not just Geotek's coring cycle, is healthy[19].
• Prestidge's first full year. Evidence the new CEO can keep buying as well and as cheaply as the founder[6].